Juice Pharma

[Whitepaper] Global Brand Lexicon – Setting the stage for a successful launch

In Orphan Drug Congress, Whitepapers by Freya Smale

Early lexicon development unifies content, accelerates understanding, and promotes rapid adoption of innovative new therapies within the rare disease community

Download whitepaper now

Transitioning an orphan drug from clinical to early-stage commercial development comes with its own unique set of communication challenges. Professionals, patients, caregivers, and advocacy groups within orphan drug communities represent some of the most active information-seeking populations in healthcare. Managing the quality, content, and timing of premarket communications are important considerations for companies planning a launch within the rare disease space.

Download whitepaper now

Participation in the development of a Global Brand Lexicon promotes collaboration

Team participation in the lexicon development process ensures that all stakeholders are able to input and feel a sense of ownership in the recommendations that will govern future brand-associated materials. While the Global Brand Lexicon provides the foundational language that will eventually evolve into product claims and promotional messaging—it can be utilized immediately in the development of  early-stage commercialization assets, becoming your Global Team’s go-to resource for:

> Congress/Convention Materials
> Unbranded Promotion
> Internal Communications
> Product Labeling
> Clinical Articles
> Educational Materials
> Medical PR
> Investor Relations

We are thrilled to announce that Juice Pharma Worldwide are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.

World Orphan Drug Congress USA 2016